Biotechnology company leveraging its immune medicine platform for diagnosing and treating diseases.
Adaptive Biotechnologies Corporation, based in Seattle, Washington, is a pioneering commercial-stage company specializing in immune medicine platforms designed to diagnose and treat a diverse array of diseases. At the core of its offerings is immunoSEQ, a robust platform and immunosequencing product that not only supports translational research endeavors but also facilitates the discovery of novel prognostic and diagnostic signals.
The company's flagship clinical diagnostic product, clonoSEQ, plays a pivotal role in detecting and monitoring minimal residual disease (MRD) in patients battling multiple myeloma, B cell acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and other lymphoid cancers. Available as a CLIA-validated laboratory developed test, clonoSEQ exemplifies Adaptive Biotechnologies' commitment to advancing precision medicine in oncology.
In addition to its diagnostic capabilities, Adaptive Biotechnologies maintains a robust pipeline of clinical products and services tailored for diagnosing, monitoring, and treating diseases such as cancer and autoimmune disorders. These innovations span applications in life sciences research, clinical diagnostics, and drug discovery, underscoring the company's comprehensive approach to improving patient outcomes through cutting-edge technology.
Founded in 2009 as Adaptive TCR Corporation and rebranded in December 2011, Adaptive Biotechnologies has forged strategic collaborations with industry leaders like Genentech, Inc., focusing on the development, manufacturing, and commercialization of neoantigen-directed T cell therapies for cancer treatment. Additionally, a partnership with Microsoft Corporation aims to pioneer diagnostic tests capable of early disease detection through a single blood sample, highlighting Adaptive Biotechnologies' leadership in leveraging technology to advance healthcare solutions globally.